Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry
Author:
Affiliation:
1. Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
2. Pfizer Inc, Brussels, Belgium
3. Pfizer Inc, Groton, CT, USA
4. Pfizer Inc, Capelle aan den IJssel, Netherlands
Funder
Pfizer Inc
AbbVie
BMS
MSD
Publisher
Oxford University Press (OUP)
Subject
Pharmacology (medical),Rheumatology
Link
http://academic.oup.com/rheumatology/article-pdf/58/3/481/27900781/key338.pdf
Reference39 articles.
1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update;Smolen;Ann Rheum Dis,2017
2. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis;Singh;Arthritis Rheumatol,2016
3. Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis;Fleischmann;RMD Open,2016
4. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression;Wells;J Rheumatol,2011
5. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register;Soliman;Ann Rheum Dis,2011
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy;Frontiers in Pharmacology;2023-09-25
2. Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia;Rheumatology;2022-01-30
3. Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis;Rheumatology and Therapy;2021-09-02
4. Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan;Frontiers in Pharmacology;2021-07-21
5. New era for outcomes and management of rheumatoid arthritis: Facing the individualized treatment challenge;Joint Bone Spine;2021-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3